Renal Biomarkers and Outcomes in Outpatients With Heart Failure Open Access
Overcarsh, Bryan Scott (2013)
Renal Biomarkers and Outcomes in Outpatients With Heart Failure
By Bryan Overcarsh
Introduction: Cystatin C and beta-2 microglobulin (B2M) may be superior renal markers compared to creatinine (Cr), blood urea nitrogen (BUN), and calculated glomerular filtration rate (GFR) in patients with acute decompensated heart failure but data in stable heart failure patients is limited.
Methods: We evaluated the association of baseline tertiles of Cr, BUN, BUN/Cr ratio, GFR (by MDRD formula), Cys-C, and B2M with clinical events and health care resource utilization (HCRU) rates in 159 outpatients (age 57.3±11.7; 103 (65%) men; 92 (58%) white; black; EF 29.5±15.2) enrolled in a prospective cohort study.
Results: Over 42±12 months (total: 560 person-years), there were 33 (20.7%) clinical events (27 deaths, 4 transplants, 2 ventricular assist device implantations), 445 all-cause admissions (170 [38.2%] for HF), and 207 emergency department (ED) visits. Among renal markers, Cr had the strongest association with clinical events, with a highest vs. lowest tertile hazard ratio of 7.30 (95% CI 1.58-33.70; P 0.01) in models adjusted for demographics (age, race, gender), LVEF, NYHA class, systolic blood pressure, serum sodium, etiology (coronary artery disease, other), and medical therapy (beta blockade, ACE inhibitor, Angiotensin receptor blocker). Cr also had the strongest association with HCRU rates. In adjusted models, the highest vs. lowest Cr tertile rate ratio was 3.02 (95% CI 1.75- 5,24; P<0.001) for all-cause admissions; 5.2 (95% CI 1.71-15.89; P<0.005) for HF admissions; and 2.89 (95% CI 1.37-6.09; P=0.005) for ED visits.
Conclusion: In outpatients with heart failure, serum Cr may be prognostically superior to other traditional and novel markers of renal function.
Table of Contents
Table of Contents
About this Master's Thesis
|Committee Chair / Thesis Advisor|
|Renal Biomarkers and Outcomes in Outpatients With Heart Failure ()||2018-08-28 14:03:52 -0400||